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The cell therapy branch of the regenerative medicine field has been innovative in developing new models of
delivery and development and identifying alternative sources of funding.We discuss the implications of these
changes for pharmaceutical companies and the opportunities they offer to a new entrepreneur.The Evolving Cell Therapy Space
Regenerative medicine, and cell therapy
in particular, is often hailed for its potential
to revolutionizemodernmedicine, and the
world seems impatient for news of both
clinical efficacy and commercial success
(Lysaght et al., 2008). While research
progresses, an increasing awareness
that established drug development and
sales models are not suited to many
aspects of cell therapy leaves the field
looking for alternative commercial para-
digms (McKernan et al., 2010). By exam-
ining the disconnect between modern
cell therapies and standard, centralized
distribution mechanisms, an entrepreneur
may find new routes to bring treatments
into mainstream patient care.
Cell therapy in the form of bone marrow
transplant has been conducted for
decades. This predominantly ‘‘point of
care’’ treatment is delivered by physicians
and hospitals with little commercial
involvement. In contrast, fibroblasts and
skin-basedproducts havebeen sold com-
mercially for years,primarily asamanufac-
tured cell-based therapy supplied by
biotechnology companies. In the last 20
years, the lines between these models
have shifted,with, for example, the expan-
sion of private cord blood banking, the
use of more differentiated blood cell
populations for immunotherapy, and the
evaluation and commercialization of non-
hematopoietic fractions of marrow for
use in wound healing, cardiac repair, and
vasculogenesis. Other typically discarded
blood products, such as red blood cells,
autologous sera, and platelet rich plasma
(PRP), may offer new sources of riches
(Brown and Kraft, 2006).
Mesenchymal stem cells (MSCs) are
a commercially attractive nonhemato-
poietic sourcematerial due to their relative
abundance and potential for long-termin vitro expansion. While their precise
differentiation potential remains debated,
MSCs and MSC-like cells offer thera-
peutic potential via their trophic and
immunemodulatory activities (see Caplan
and Correa, 2011, this issue). Even more
recently, a candidate blood-vessel-form-
ing stem cell has been identified, and
companies have been formed to try and
leverage the utility of this population
(Angioblast Systems, Inc; Mesoblast Ltd).
In the neural field, stem and progenitor
cells have been sourced from fetal tissue,
which clearly is not predisposed to an
industrial scale. However, the develop-
ment of protocols to derive neural stem
cells (NSCs) and their progeny from
pluripotent stem cells has opened new
commercial doors. Geron and ACT are
two examples of companies that have
approved investigational new drug appli-
cations (INDs) that are currently enrolling
patients.
Within the induced pluripotent stem cell
space, the rapid pace of discovery that
brought nonintegrative, high-efficiency re-
programming strategies, GMP compliant
methods, and protocols for directed
differentiation has made the idea of
personalized medicine more real, though
it remains a long way off. The short-term
commercial potential offered by these
advances will likely be based in drug
discovery and toxicity testing, as dis-
cussed below.
The current revival of gene therapy
brings an additional dimension to the
evolution of commercial cell therapies.
Previously hampered by issues with
random integration and challenges in
achieving localized tissue delivery, plurip-
otent cells can now be readily engineered
and differentiated to yield cells with
specific homing properties, which opens
the door to ex vivo gene therapy coupledCell Stemwith cell transplants. A few brave
pioneers, including researchers at the
New York Stem Cell Foundation, have
begun testing such efforts.
Both Europe and the US have re-
sponded to the evolving landscape with
new regulatory paradigms for cell therapy
(Fink, 2009). Broadly, the FDA differenti-
ates between minimally manipulated,
autologous cells used for a homologous
function and those that are manufactured
or used in a nonhomologous manner,
with the former needing to satisfy fewer
and simpler rules. Such regulatory distinc-
tions influence the design of commercial
activity, in particular by broadly dividing
the field into autologous and allogeneic
efforts. MSC-based therapies fall into
both domains, and NSCs are probably
the closest to the market in the allogeneic
domain. However, the pace of research—
particularly in the pluripotent cell sphere—
has forced companies to reevaluate their
business models.
Standard Drug Development
Models for Cell Therapy?
Historically, development of new thera-
pies has occurred in industry, typically
led by big pharmaceutical or biotech-
nology companies. In the classic model,
a university’s technology transfer depart-
ment helps patent an academic’s inven-
tion and license it to potential early inves-
tors. Experienced investors can forecast
the cost of taking a therapy to market
and can evaluate the risk associated
with a given process. In the US, universi-
ties and the government share invention
revenues with the inventor, providing
incentive for innovation. Moreover, an
active, relatively profitable pharmaceu-
tical industry with the infrastructure to
navigate regulatory, marketing, and reim-
bursement channels offers inventors andCell 9, July 8, 2011 ª2011 Elsevier Inc. 7
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to avoid having to incur the cost of
commercialization. Following this model,
new drugs cost somewhere between
$200M to $1 billion to develop, take 10–
15 years to get to market, and have the
potential to generate several billions of
dollars in sales. Perhaps one in ten prom-
ising drug candidates will pass regulatory
approval, and thus companies expect
a certain timeline of exclusivity based on
patent protection in order to offset both
the risk and their development costs.
This small molecule drug development
model has been successfully adapted to
biologics, and while there have been
attempts to apply this framework to cell
therapy, a number of issues suggest that
new paradigms are needed. Indeed,
despite its historical success, it is unclear
if the standard model is sustainable even
for ongoing small molecule drug develop-
ment. Costs for drug development have
risen faster than inflation, success rates
have fallen and the number of late stage
failures has risen, all of which make the
process less viable. Governments faced
with rising healthcare costs and an aging
population are unwilling to subsidize the
research effort, and payers are unwilling
to shoulder the high cost of a new medi-
cation for only marginal improvement
over existing therapy. Indeed, the ongoing
pharma evolution is likely a result of
a failure of thismodel in a rapidly changing
healthcare environment. Considering that
cell therapies offer a host of new practical
challenges relative to small molecule
drug candidates, it seems reasonable to
predict that adapting this model to regen-
erative medicine will not work.
There are several reasons why cell-
based therapy will likely be developed
under a new commercial paradigm, not
the least of which is because most phar-
maceutical companies are reluctant to
adopt cells as an alternative to small
molecules. This decision is in large part
a practical matter, given that standard
small molecule manufacturing facilities
cannot be adapted to cell production.
Even the manufacture of biologics, which
do involve cell culture, is designed to save
the supernatant and discard the cells, and
the effort required to convert existing
bioreactor technology to reverse this
process is difficult.
Even if the cell therapy products could
be produced, the animal models de-8 Cell Stem Cell 9, July 8, 2011 ª2011 Elsevisigned to test the efficacy of small mole-
cules are different, and modeling cell
based therapy tends to have added re-
quirements for followup, safety, and anal-
ysis. Likewise, standard clinical studies
require major modifications, since while
a drug has a definite half-life and likely
functions similarly in vitro and in vivo, cell
fates vary in different contexts, and trans-
planted stem cells may persist for years,
or even a lifetime. Similarly, strategies to
avoid immune reactions to antibodies
and growth factors are relatively clear-
cut, but these solutions are not applicable
to cell-based therapy, which is more
akin to organ transplantation. Expertise
therefore lies with clinicians and hospitals
rather than pharmaceutical companies.
While these specific traits that distin-
guish cell-based therapy from more con-
ventional drug development are equally
problematic for other cell therapy practi-
tioners, large pharmaceutical companies
exhibit strong reluctance to change what
works, given the huge overhead outlay
required to make such changes. Indeed,
as pharmaceutical companies slowly
begin to move toward cell therapy, they
are abandoning old processes and adopt-
ing novel methodologies.
Venture Capitalists Have Been
Reluctant to Fund Cell-Based
Therapies
Beyond the question of pharma’s willing-
ness to adapt their development strategy
and manufacturing infrastructure, the
partnership between universities, tech
transfer, and investors is not as robust
as it was for small molecule development.
Large venture capital firms have also been
reluctant to fund cell-based therapy
companies. In general, venture capitalists
calculate the potential return on their
investment, the time it will take to get
that potential return, and the risk related
to that return. A higher risk can be justified
if the return is larger and the timeline to re-
turn short. Conversely, less money will be
placed at risk if the timeline is longer or the
perceived risk is higher.
In the minds of most investors, cell
therapy has a long timeline to a potential
return, and the field is too young to
reliably predict which candidates will
be blockbusters. Furthermore, the next
wave of stem cell therapies may only offer
incremental improvements over existing
options. In addition to the scientific risker Inc.in investing in a new cellular product,
there are also ethical risks associated
with the public divide on pluripotent cell-
based therapy, and the resulting political
risk and uncertainty that stems from a
lack of global harmonization with respect
to regulatory oversight (Harvey, 2009;
Bergman and Graff, 2007).
Given that other opportunities with
lower risk and higher predicted return
are available, venture capitalists will
therefore allocate less capital to this field
and invest elsewhere. It is worth noting
that these arguments are not theoretical
and clearly have affected money inflows.
Virtually all major NIH funding has gone
to adult stem cells or non-ESC based
therapies, which carry less ethical, polit-
ical, and scientific risk, or has gone to
fund alternate uses (nontherapeutic uses
of cells) such as discovery or screening
models or toxicological applications.
Centralized or Distributed?
The question of novel infrastructure
needed for themanufacture of cell therapy
products is most relevant for models that
involve allogeneic cell sources. Autolo-
gous products, or evenminimally manipu-
lated allogenic cells, will likely fall under
a distributed or personalized therapy
model. In contrast, pharmaceutical com-
panies typically utilize a centralized
distribution model in which the standard-
ized product is generated in bulk and
supplied in batches to medical providers.
As mentioned above, the regulations that
will apply to this approach are still not
clear. In addition to more straightforward
regulatory oversight, the personalized dis-
tributed model can often deliver therapy
thatmay bequicker to develop, and there-
fore cheaper per unit dose (Enserink,
2006). Furthermore, an autologous model
may be perceived as better, since one’s
own cells are being used for therapy.
Nonetheless, distributed models may
be harder to commercialize, at least in
a traditional, scalable way. One compro-
mise approach has investors focus on
a smaller subset of adult cell-based
therapies that carry few political and
ethical risks, and can be adopted to
large-scale bioreactor manufacturing.
Indeed, a quick sampling of successfully
funded cell-based companies reveals
that MSC-based companies such as
Osiris, Athersys, Mesoblast, and Stem-
peutics dominate the market.
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to utilize cells for discovery and other
ancillary activities like tool or reagent
development. For example, companies
such as CDI, Iperian, and FATE are
all based on discovery or toxicological
assays, and have been remarkably
successful in raising funds. Interestingly,
tool and reagent companies that provide
key resources for cell-based discovery
and therapeutics have also been quite
successful in the marketplace, though
not as successful in raising investment
money, perhaps because this sort of
venture does not typically generate a
high return on investment. Nevertheless,
these smaller tool and reagent companies
promote rapid dissemination of tech-
nology and provide a means of standard-
ization globally. Close to a dozen small
tool and technology companies that offer
iPSC-related reagents have been formed
in the last 2 years in California alone.
Intellectual Property in a Stem Cell
Era
Any organization developing a new
discovery, whether pharma, venture capi-
tal firms, or even academic spin-offs,
will need to navigate a complex patent
landscape. From a stem cell perspective,
this space is even more complicated
because several countries have deemed
that human ESCs and pluripotent cells
cannot be patented. Given that industry
is global and any treatment can be
administered anywhere, it has become
hard to determine how and when to
protect intellectual property. Furthermore,
patents require a specifically defined
product, such as an exact chemical
formula, a precise mass spec signature,
or a defined sequence. Cells do not fall
into such neat definitions. Cells change
in response to the environment and
many distinct cell populations may have
similar functions in vivo (see for example
the multiplicity of MSC types). This issue
has created extreme difficulty in obtaining
either exclusivity or first mover advantage
and has been a factor that has inhibited
investment in the field.
How are Other Companies
Surviving?
The wonderful thing about capitalism is
that opportunity leads to entrepreneur-
ship, and often to successful new busi-
ness models. Profitable cell therapy-based businesses have been developed
in a variety of ways.
For example, in the absence of venture
funding and the relative dearth of tools
and reagents, government agencies
such as the NIH and state governments
have stepped in to provide support,
with California leading the way. Viacyte,
a pancreatic islet-based therapeutic
company, received grants in the form
of loans from the California Institute
of Regenerative Medicine (CIRM). This
funding is nondilutive; CIRM does not
receive a fraction of ownership in return
for their capital, which leaves Viacyte
with more ownership available to attract
venture investors. Meanwhile, NIH’s
orphan disease program fills a critical
niche (Freeman et al., 2010), in part
through the PACT program that has
supplied GMP-grade cells to many early
innovators.
In the absence of public or government
support of public banking, cord blood
companies have developed a hybrid
model of private/public banking that has
allowed them to thrive and make an
otherwise discarded cell population avail-
able for potential therapeutic use. These
companies developed a subscription
model with a storage fee that has become
a viable biorepository model for process-
ing and storage of other cell types.
Hospitals and private physician groups
have established personalized medicine
clinics that offer a range of cells for
a variety of uses. Such clinics are legal
but not well regulated and are often
prone to wild claims (Lau et al., 2008).
Others, however, are quite reputable and
provide important services. These clinics
are largely self-funded, and given their
rapid spread, are likely quite profitable.
Some of the larger clinics have nowbegun
trials and funded studies to verify their
claims, and are therefore contributing,
albeit to a small extent, to the scientific
database.
Some hospitals have set up stem cell
laboratories that provide clinical-grade
cells processed on site by experienced
and trained personnel for marrow, ortho-
pedic, and immunotherapy applications.
Device companies have partnered with
hospitals to fund trials and develop
customized devices for these procedures.
Thermogeneis, Harvest, Stryker, andCari-
dian are examples of companies that have
undertaken this sort of interaction.Cell StemOther, braver companies have begun
examining if a modified version of person-
alized therapy can be combined with
a centralized processing facility to pro-
vide therapy that would be subject to
more extensive regulation than a purely
autologous, distributed model. Carticell
from Genzyme is one such example.
More recently, however, other companies
have been able to both raise capital and
develop a product. Aastrom, for example,
collects marrow-derived tissue repair
cells (TRCs) from a patient and transfers
them to a central site for a multiple-week
processing period, after which the cells
are returned to a hospital site to treat the
patient’s critical limb ischemia.
While these models have allowed some
companies to bypass the need for funding
from traditional sources, other ventures
have sought public investment, because
their capital requirements were too large
to rely on government largess alone, and
the specific application was considered
too long-term or too high-risk for venture
capitalists, hospitals, and pharmaceutical
companies. These companies managed
to tap the public enthusiasm for stem
cells and their therapeutic potential.
Early-stage companies who otherwise
would not have been considered viable
initial public offering (IPO) candidates
have been able to go public, thus bypass-
ing several stages of private investment.
Some companies have been even more
creative and have used reverse mergers
as a ‘‘backdoor’’ alternative to going
public. In this case, a privately held
company merges with an existing, but
essentially inactive publicly traded com-
pany. Thus, the private company can
become public without the usual costs,
time, and scrutiny that are typically
involved. There is a long list of such
reverse mergers (Neostem, Stem Cell
Inc., etc), which give small, capital-
starved companies access to the market.
I expect this trend will continue into the
foreseeable future.
What Should a New Entrepreneur
Do?
Although there is no prescription for
success, there are several critical stages
at which specific decisions can influence
the outcome of your venture. Perhaps
the earliest decision point is whether or
not to patent your idea. Patents are very
powerful and provide a clear method ofCell 9, July 8, 2011 ª2011 Elsevier Inc. 9
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expensive, have to be published, and
can often be bypassed. Prosecuting
them worldwide is difficult and the regula-
tions governing stem cells vary country
to country, making it difficult to get
global coverage in what is now a global
economy.Protecting somethingasa trade
secret may be an alternative in the cell
therapy space.
A second important decision is when
to set up a company and begin the
process of commercialization. My experi-
ence suggests that most inventors tend to
commercialize too early and, as a result,
lose control over their invention and
find their ownership diluted as they sell
progressively more of the company to
investors to generate the requisite capital.
Nondilutive financing such as research
grants, support from your parent institu-
tion, government funding in the form of
small business innovation research grants
(SBIRs) and small business technology
transfer programs (STTRs), and even
support from other small companies in
the form of cross licensing, space, and
shared resources can be important to
success. The further you can develop
your idea, the lower the risk for venture
capitalists, the shorter the time to return
on their equity investment, and therefore
the higher the price they are willing to
pay. There is of course the corresponding
issue of how can you develop an idea
or a therapy at the early stage without
forming a company, and this is an
issue that is being actively explored.
Universities are increasingly functioning
as partners and building bioparks to allow
investigators to begin work while retain-
ing academic appointments. Technology
transfer offices are working with angel
investors to provide funding, and several
public-private partnerships between
foundations and companies have sprung
up to help this early-stage effort without
diluting ownership. Tapping into these
nascent strategies requires work, but it
is well worth the effort in the long run.10 Cell Stem Cell 9, July 8, 2011 ª2011 ElsevChoose your investment partner wisely
as they need to either have deep pockets
or additional partners on tap for the inevi-
table additional rounds of financing one
may need. In general, finding an invest-
ment partner who brings more than
just money to the table is often of greater
value than someone with deep pockets
alone. The partner may bring manage-
ment expertise, technical expertise (such
as within an investment arm of pharma
or via a stable of companies in a large
venture fund), or complimentary know-
how.
Think globally, as the market and
competition are now global (Salter et al.,
2006, 2007), and indeed at least in the
stem cell field, atypical sources of funding
have to be considered. For example,
several small companies have looked to
India, simply because there are hospital
partners who are willing to invest and
help run clinical trials for cell-based
therapy. Others are looking to establish
offices in California to access resources
there and tap American markets.
Access information, and use available
resources. There are numerous sources
of information and many experts and it is
important to both collect such information
and sift through it to identify key issues in
this rapidly changing field. New informa-
tion may make your model obsolete,
may identify new competition or a key
technology that is a must-have, or may
become available to accelerate your
efforts. It does notmatter what it is—infor-
mation is crucial in making considered
decisions, and an investigator/entrepre-
neur cannot ignore the outside world
while focusing on the invention itself.
Conclusions
Although there are many hurdles to being
a successful entrepreneur in the field
of cell-based applications, it is neverthe-
less very possible. The field is large and
growing. Many different models have
been successful and creative pioneers
have shown what can work, and equallyier Inc.importantly, what does not. One can
choose to learn from the experience of
others, and with a careful detailed plan,
one can succeed.
Many of the hurdles I have described
are already becoming less of a challenge.
Technical advances will overcome some
issues, such as integration-free iPSC
reprogramming. Pharma has begun to
invest in this field. The economy is in
recovery and venture funds are becoming
more active. Government policies have
been more stable and federal funding in
the US and internationally has increased
in recent years. The regulatory authorities
have approved cell-based therapy and
several INDs in the stem cell field, demon-
strating that they feel comfortable with the
path forward.
I remain optimistic that we will see
many more successes in the near future.REFERENCES
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